Anakinra
Top View
- Scientific Abstracts Thursday, 15 June 2017
- COVID19 As Immunology Boot Camp: Anti-Viral Defense, Cytokine Biology & Prospects for Therapy
- Standard Dose of Ustekinumab for Childhood-Onset Deficiency of Interleukin–36 Receptor Antagonist
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Oo-()-No,O Ra50
- Anakinra Effective for Resistant FMF In
- CIMZIA (Certolizumab Pegol) for Injection, for Subcutaneous Use CIMZIA (Certolizumab Pegol) Injection, for Subcutaneous Use ------CONTRAINDICATIONS------ Initial U.S
- Tims) – Unified Formulary
- BIOLOGICS & What You Need to Know
- Multisystem Inflammatory Syndrome in Children (MIS-C) Pathway
- AN INTRODUCTION to KINERET® (Anakinra) Information and Tips to Help Your Patient Get Started KINERET® (Anakinra) and YOU
- Medications That Are Immunosuppressive Or Immunomodulatory (This List Is Not All-Inclusive)
- Anakinra After Treatment with Corticosteroids Alone Or with Tocilizumab in Patients with Severe COVID-19 Pneumonia and Moderate
- International Nonproprietary Names for Biological and Biotechnological Substances: a Review17
- Systemic Therapy with Conventional and Novel Immunomodulatory Agents for Ocular Inflammatory Disease
- Salvage Therapy for Refractory Hemophagocytic Lymphohistiocytosis: a Review of the Published Experience
- Comparative Effectiveness of Biological Medicines in Rheumatoid Arthritis
- (12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar